Group 1: Production Expansion - The company is expanding its coenzyme Q10 production capacity to 920 tons annually, driven by increasing market demand and application scenarios [2] - The production capacity will be gradually released in the future, helping to consolidate the company's leading position in the industry and expand market share [2] Group 2: Profit Margin Improvement - The gross margin for coenzyme Q10 has increased year-on-year due to external procurement last year, which raised raw material costs, and improvements in scale effects and technology upgrades that reduced unit costs in the first three quarters of this year [2] Group 3: Marketing Strategy for Doctor's Best - Doctor's Best is a well-established brand in the nutritional supplement market, known for its diverse product matrix and scientific formulations, experiencing rapid sales growth in China [3] - The company plans to increase investment in brand building and enhance market penetration in China through proactive and pragmatic strategies [3] Group 4: Leveraging Dual Advantages - The company has established a full industry chain layout, including raw material factories, finished product production, and terminal brands [3] - Future strategies will focus on strengthening core business segments and leveraging the entire industry chain to achieve synergistic value between raw materials and brands [3]

Group 1 - The food processing sector increased by 0.31% on November 12, with Anjijia Food leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] - Anjijia Food's closing price was 81.22, reflecting a rise of 5.19% with a trading volume of 184,000 shares and a transaction value of 1.509 billion yuan [1] Group 2 - The food processing sector experienced a net outflow of 275 million yuan from institutional investors, while retail investors saw a net inflow of 239 million yuan [2] - The top gainers in the food processing sector included Qianwei Central Kitchen and Xianle Health, with closing prices of 41.48 and 25.23, respectively, reflecting increases of 2.75% and 1.77% [1] - The sector's main stocks showed varied performance, with some experiencing significant declines, such as Gaisijia Food, which fell by 7.31% [2]

关于厦门金达威集团股份有限公司 2025 年第三次临时股东会的 法 律 意 见 书 福建至理律师事务所 地址：中国福州市鼓楼区洪山园路华润万象城三期 TB#写字楼 22 层 邮政编码：350025 电话：（86 591）8806 5558 传真：（86 591）8806 8008 网址：http://www.zenithlawyer.com 1 福建至理律师事务所（以下简称本所）接受厦门金达威集团股份有限公司（以 下简称公司）之委托，指派蒋慧、韩叙律师出席公司 2025 年第三次临时股东会 （以下简称本次会议），并依据《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）、《上市公司股东会规则)》《深 圳证券交易所上市公司股东会网络投票实施细则》（以下简称《网络投票实施细 则》）等有关法律、行政法规、规章、规范性文件以及《厦门金达威集团股份有 限公司章程》（以下简称《公司章程》）之规定出具法律意见。 对于本法律意见书，本所特作如下声明： 1.本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则(试行)》等规定及本法律意 ...

| 证券代码：002626 | 证券简称：金达威 | 公告编号：2025-094 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 厦门金达威集团股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会议无否决提案的情形； 2.本次股东会议无变更以往股东会议已通过的决议。 一、会议召开和出席情况 6. 现场会议主持人：董事长兼总经理江斌先生 本次会议的召集和召开符合《公司法》《深圳证券交易所股票上市规则》《上 市公司股东会规则》及《公司章程》等有关法律、法规和相关规范性文件规定。 （二）会议出席情况 股东出席的总体情况： 通过现场和网络投票的股东 211 人，代表股份 219,112,397 股，占公司有表 决权股份总数的 35.9239％。 （一）会议召开情况 1. 现场会议召开时间：2025 年 11 月 10 日 14:30 开始 2. 网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时间 为：2025 年 11 月 1 ...

Market Performance - The food processing sector increased by 2.71% on November 10, with Huifa Food leading the gains [1] - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] Individual Stock Performance - Huifa Food (603536) closed at 14.08, up 10.00% with a trading volume of 250,700 shares and a transaction value of 337 million [1] - Baba Food (605338) closed at 30.72, up 9.99% with a trading volume of 96,200 shares and a transaction value of 285 million [1] - Other notable performers include: - Gais Food (920826) at 15.12, up 8.78% [1] - Anjiyuan Food (603345) at 78.08, up 5.26% [1] - Kangbiter (920429) at 18.08, up 3.91% [1] Capital Flow Analysis - The food processing sector saw a net inflow of 134 million from institutional investors, while retail investors experienced a net outflow of 150 million [2] - The main stocks with significant capital inflow include: - Anjiyuan Food with a net inflow of 78.45 million [3] - Huifa Food with a net inflow of 50.57 million [3] - Baba Food with a net inflow of 44.80 million [3]

Core Viewpoint - The company, Kingdawei (002626.SZ), clarified that it does not produce any drugs related to the treatment of influenza and focuses on providing high-quality nutritional health solutions [1] Group 1 - The company is registered in Xiamen, Fujian Province [1] - Kingdawei offers Doctor's Best nutritional supplements that provide various immune-related nutrients [1] - The products are designed to help maintain normal bodily functions [1]

Core Viewpoint - The company Jin Da Wei (002626.SZ) clarified that it does not produce any drugs related to the treatment of influenza, focusing instead on providing high-quality nutritional health solutions [1] Group 1 - The company is registered in Xiamen, Fujian Province [1] - Jin Da Wei is dedicated to offering various immune-related nutrients through its Doctor's Best nutritional supplements, which help maintain normal bodily functions [1]

1. Reported Industry and Investment Rating - The reported industry is food and beverage. There is no information on investment rating in the provided content. [2] 2. Core Viewpoints - In 2025, the company focused on its main business, effectively integrated resources, reduced costs, and achieved double - growth in revenue and profit in a complex global environment. [22] - The company's expansion of Coenzyme Q10 production is based on market growth expectations, which will help consolidate its leading position in the industry and expand its market share. [25] - The company aims to build a complete industrial ecosystem through full - industry - chain and domestic - international layout, and will continue to strengthen relevant business segments. [27] 3. Summary by Relevant Catalogs 3.1. Research Basic Situation - The research object is Jindawei, belonging to the food and beverage industry. The reception time was November 5, 2025. The listed company's reception staff included the board secretary Li Xiaofang, the securities affairs representative Lin Jie, and the securities affairs specialist Zhang Yanting. [17] 3.2. Detailed Research Institutions - Representatives from the fund management company, including Yu Yue, Zheng Zheng, and He Baohua, from Boshi Fund, participated in the research. [20] 3.3. Research Institution Proportion - There is no relevant information provided. [21] 3.4. Main Content Data - **Overall performance in the first three quarters**: In 2025 from January to September, the company achieved an operating income of 2.604 billion yuan, a year - on - year increase of 11.16%; the net profit attributable to shareholders of the listed company was 361 million yuan, a year - on - year increase of 63.47%; the non - recurring profit and loss net profit was 349 million yuan, a year - on - year increase of 56.22%. [22] - **Performance of Coenzyme Q10 in the first three quarters**: The Coenzyme Q10 reconstruction and expansion project is progressing smoothly, and the annual production capacity will reach 920 tons after full production. In the first three quarters of 2025, its sales revenue, sales volume, and gross profit margin all increased compared to the same period last year. [23] - **View on Coenzyme Q10 expansion**: The expansion is based on market growth expectations. The main consumer country is the United States, and emerging markets like China have great potential. The expansion will help maintain and expand the company's market share, and the gross profit margin has remained good in recent years. [25] - **Performance of Doctor's Best in the first three quarters**: It is a 35 - year - old mature brand in the US, with nearly 80% of sales achieved overseas through well - known online platforms, having a high repurchase rate. Its revenue and profit both increased in the first three quarters of this year. [26] - **Domestic sales of Doctor's Best**: The brand has various product matrices in China, with products such as Coenzyme Q10, Ergothioneine, NAD +, magnesium, vitamin K, and D being the most popular. Its revenue and profit also increased in the first three quarters of this year, and the company is highly involved in the Double 11 event. [27] - **View on each business segment**: The company focuses on the global health industry, with a full - industry - chain layout. It will continue to strengthen relevant segments and leverage the advantages of the full - industry - chain layout to enable production and brand to empower each other. [27]

Core Viewpoint - The company announced that its coenzyme Q10 expansion project is progressing well, with an expected annual production capacity of 920 tons upon full completion [1] Group 1: Company Performance - Coenzyme Q10 is one of the company's main products, and its sales revenue, sales volume, and gross margin have all increased compared to the same period last year [1] - The company maintains a leading position in the coenzyme Q10 industry for the first three quarters of 2025 [1] Group 2: Project Development - The infrastructure for the coenzyme Q10 expansion project has been largely completed, and production capacity is gradually ramping up [1]

Core Viewpoint - The company Jin Dawei (002626) announced on November 5 that it is expanding its production of Coenzyme Q10 due to the increasing market demand driven by its health benefits in cardiovascular health and anti-aging [1] Industry Summary - Coenzyme Q10 is widely used in nutritional supplements, food additives, pharmaceuticals, and cosmetics, with a growing market demand [1] - The primary consumer market for Coenzyme Q10 is the United States, but emerging markets like China are seen as having significant potential [1] Company Summary - The company's expansion of Coenzyme Q10 production is based on market growth expectations and aims to solidify its leading position in the industry [1] - The company has maintained a good gross margin for Coenzyme Q10 over the past few years [1]